Announcements
Sidley Represents Respira in Its Option to Be Acquired by Gossamer Bio
September 30, 2025
Sidley represented Respira Therapeutics, Inc., a Samsara BioCapital portfolio company, in its agreement granting an option to Gossamer Bio, Inc. (Nasdaq: GOSS) to acquire the company. Respira is developing RT234 (vardenafil inhalation powder) as the first as-needed therapy for use in pulmonary hypertension.
The Sidley team was led by partner Jason Kropp and counsel Rebecca Nauta (Emerging Companies and Venture Capital), and included Dr. Christian Brause and Andy Lau (Tax); Nicholas Frey (Employee Benefits and Executive Compensation); Lauren Grau (Technology and Life Sciences Transactions); and Ethan McMahon and Margalit Zimand (M&A).
Contacts
Capabilities
Suggested News & Insights
Sidley Ranked in Chambers Asia-Pacific 2026December 11, 2025Sidley Represents JOLT in its Agreement to Acquire Assets from Volta Media NetworkDecember 10, 2025Sidley Represents Jane Street in Investments in Kraken and X-EnergyDecember 3, 2025Sidley Represents Nuvalent in Pricing of US$500 Million Public OfferingNovember 20, 2025Sidley Represents RA Capital Management in Artios Pharma’s US$115 million Series D FundingNovember 20, 2025Sidley Represents Itron in Its US$525 Million Definitive Agreement to Acquire LocusviewNovember 17, 2025
- Stay Up To DateSubscribe to Sidley Publications
- Follow Sidley on Social MediaSocial Media Directory